The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Louise Emmett
Honoraria - Astellas Pharma; AstraZeneca; Janssen Oncology; Mundipharma; Telix Pharmaceuticals
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Lavinia Anne Spain
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Ventana Medical Systems (Inst)
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Angelyn Anton
Honoraria - Amgen; Eisai; Janssen-Cilag
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Mundipharma (Inst)
 
Roslyn Wallace
No Relationships to Disclose
 
Anupama Pasam
No Relationships to Disclose
 
Mathias Bressel
No Relationships to Disclose
 
Erin Cassidy
No Relationships to Disclose
 
Patricia Banks
No Relationships to Disclose
 
Nattakorn Dhiantravan
No Relationships to Disclose
 
Timothy J. Akhurst
No Relationships to Disclose
 
Aravind Ravi Kumar
No Relationships to Disclose
 
Ramin Alipour
No Relationships to Disclose
 
Mark Scalzo
No Relationships to Disclose
 
Scott Williams
Consulting or Advisory Role - Amgen; Janssen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Rodney Hicks
Stock and Other Ownership Interests - Telix Pharmaceuticals
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen